Moderna to Provide Israel With 4 Million More Vaccine Doses
Moderna (MRNA) - Get Moderna, Inc. Report will be delivering four million more doses of its covid-19 vaccine to Israel, on top of two million already supplied, according to a company statement.
The Cambridge, Mass., drugmaker already had begun the review process with the ministry and was awaiting review for emergency-use authorization in the U.S.
On Monday, Moderna said that its late-stage, or Phase 3, trial of its vaccine in 196 cases confirmed a 94.1% efficacy rate, nearing the 95% threshold reported by Pfizer (PFE) - Get Pfizer Inc. Report for its vaccine. The Phase 3 trial involves more than 30,000 participants.
The company also noted that its product can last as long as six months when stored at standard freezer temperatures of minus-4 degrees Fahrenheit, compared with the minus-94 degree temperature the Pfizer vaccine requires.
TheStreet Recommends
Moderna also said that it was working to increase manufacturing to deliver around 500 million doses of its vaccine a year, and perhaps up to 1 billion doses a year, starting in 2021.
Moderna shares had surged to a record on Tuesday after the biotech filed for marketing approval from European health authorities for its coronavirus vaccine
The company, which on Monday reported a 100% efficacy rate against severe forms of covid-19 from late-stage trials of its mRNA-based vaccine, will likely get a decision from the European Medicines Agency on Jan. 12, officials indicated.
A similar application was made by Pfizer and its German partner BioNTech (BNTX) - Get BioNTech SE Report earlier Tuesday, with the EMA indicating a final verdict on Dec. 29.
Moderna on Monday filed its application for emergency use with the U.S. Food and Drug Administration, with an assessment scheduled for Dec. 17.
